21 related articles for article (PubMed ID: 38468547)
1. A Prospective Study of Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience.
Lévesque F; Payne RJ; Beaudoin D; Boucher A; Fortier PH; Massicotte MH; Pusztaszeri M; Rondeau G; Corriveau E; El Malt F; Brassard M
J Clin Endocrinol Metab; 2024 May; ():. PubMed ID: 38779881
[TBL] [Abstract][Full Text] [Related]
2. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
3. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
[TBL] [Abstract][Full Text] [Related]
4. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
[TBL] [Abstract][Full Text] [Related]
5. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
6. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
[No Abstract] [Full Text] [Related]
7. Repeat Fine-Needle Aspiration With Molecular Analysis in Management of Indeterminate Thyroid Nodules.
Papazian MR; Dublin JC; Patel KN; Oweity T; Jacobson AS; Brandler TC; Givi B
Otolaryngol Head Neck Surg; 2023 Apr; 168(4):738-744. PubMed ID: 35412868
[TBL] [Abstract][Full Text] [Related]
8. Molecular testing for indeterminate thyroid nodules: past, present, and future.
Raghunathan R; Praw SS; Livhits M
Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):231-237. PubMed ID: 37530703
[TBL] [Abstract][Full Text] [Related]
9. Molecular Testing for Bethesda III Thyroid Nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution.
Stillman MD; Kuo EJ; Liou R; Almuqate A; Virk R; Lee JA; Kuo JH; McManus CM
Thyroid; 2024 Apr; 34(4):460-466. PubMed ID: 38468547
[No Abstract] [Full Text] [Related]
10. Analysis of the bethesda system for reporting thyroid cytopathology and similar precursor thyroid cytopathology reporting schemes.
Wong LQ; Baloch ZW
Adv Anat Pathol; 2012 Sep; 19(5):313-9. PubMed ID: 22885380
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
